Atea Pharmaceuticals (AVIR) Change in Accured Expenses (2019 - 2026)

Atea Pharmaceuticals' Change in Accured Expenses history runs 8 years deep, the most recent figure standing at -$2.7 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 880.69% year-over-year to -$2.7 million in Q1 2026; TTM through Mar 2026 was $9.6 million, a 282.45% increase from a year earlier, with the FY2025 full-year figure at $12.7 million, up 194.26% from the prior year.
• Change in Accured Expenses fell to -$2.7 million in Q1 2026 per AVIR's latest filing, from $9.7 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $9.8 million in Q4 2023 and bottomed at -$28.0 million in Q1 2022.
• The 5-year median for Change in Accured Expenses is $347000.0 (2025), against an average of -$1.7 million.
• Across the five-year window, Change in Accured Expenses soared 556.59% in 2023 and plunged 880.69% in 2026, its largest moves.
• Year by year, Change in Accured Expenses stood at $1.5 million in 2022, then surged by 556.59% to $9.8 million in 2023, then slumped by 152.42% to -$5.1 million in 2024, then soared by 290.21% to $9.7 million in 2025, then tumbled by 127.84% to -$2.7 million in 2026.
• Per Business Quant, the three latest AVIR Change in Accured Expenses figures stand at -$2.7 million (Q1 2026), $9.7 million (Q4 2025), and $5.5 million (Q3 2025).